Beneficial Consequences of One-Month Oral Treatment with Cannabis Oil on Cardiac Hypertrophy and the Mitochondrial Pool in Spontaneously Hypertensive Rats
Restricted accessResearch articleFirst published online February, 2025
Beneficial Consequences of One-Month Oral Treatment with Cannabis Oil on Cardiac Hypertrophy and the Mitochondrial Pool in Spontaneously Hypertensive Rats
It has been demonstrated the dysregulation of the cardiac endocannabinoid system in cardiovascular diseases. Thus, the modulation of this system through the administration of phytocannabinoids present in medicinal cannabis oil (CO) emerges as a promising therapeutic approach. Furthermore, phytocannabinoids exhibit potent antioxidant properties, making them highly desirable in the treatment of cardiac pathologies, such as hypertension-induced cardiac hypertrophy (CH).
Objective:
To evaluate the effect of CO treatment on hypertrophy and mitochondrial status in spontaneously hypertensive rat (SHR) hearts.
Methods:
Three-month-old male SHR were randomly assigned to CO or olive oil (vehicle) oral treatment for 1 month. We evaluated cardiac mass and histology, mitochondrial dynamics, membrane potential, area and density, myocardial reactive oxygen species (ROS) production, superoxide dismutase (SOD), and citrate synthase (CS) activity and expression. Data are presented as mean ± SEM (n) and compared by t-test, or two-way ANOVA and Bonferroni post hoc test were used as appropriate. p < 0.05 was considered statistically significant.
Results:
CH was reduced by CO treatment, as indicated by the left ventricular weight/tibia length ratio, left ventricular mass index, myocyte cross-sectional area, and left ventricle collagen volume fraction. The ejection fraction was preserved in the CO-treated group despite the persistence of elevated systolic blood pressure and the reduction in CH. Mitochondrial membrane potential was improved and mitochondrial biogenesis, dynamics, area, and density were all increased by treatment. Moreover, the activity and expression of the CS were enhanced by treatment, whereas ROS production was decreased and the antioxidant activity of SOD increased by CO administration.
Conclusion:
Based on the mentioned results, we propose that 1-month oral treatment with CO is effective to reduce hypertrophy, improve the mitochondrial pool and increase the antioxidant capacity in SHR hearts.
HouJ, KangYJ. Regression of pathological cardiac hypertrophy: Signaling pathways and therapeutic targets. Pharmacol Ther, 2012; 135(3):337–354; doi: 10.1016/j.pharmthera.2012.06.006
3.
SaheeraS, KrishnamurthyP. Cardiovascular changes associated with hypertensive heart disease and aging. Cell Transplant, 2020; 29:963689720920830; doi: 10.1177/0963689720920830/ASSET/IMAGES/LARGE/10.1177_0963689720920830-FIG1.JPEG
4.
EirinA, LermanA, LermanLO. Mitochondrial injury and dysfunction in hypertension-induced cardiac damage. Eur Heart J, 2014; 35(46):3258–3266; doi: 10.1093/EURHEARTJ/EHU436
5.
Wei LiuC, WangX, Yen NguyenB, et al.Mitochondrial function in the heart: The insight into mechanisms and therapeutic potentials. Br J Pharmacol, 2018; 176(22):4302–4318; doi: 10.1111/bph.14431
6.
CortassaS, JuhaszovaM, AonMA, et al.Mitochondrial Ca 2+, redox environment and ros emission in heart failure: Two sides of the same coin? HHS Public Access. J Mol Cell Cardiol, 2021; 151:113–125; doi: 10.1016/j.yjmcc.2020.11.013
7.
ZorovDB, JuhaszovaM, SollottSJ. Mitochondrial Reactive Oxygen Species (ROS) and ROS-induced ROS release. Physiol Rev, 2014; 94(3):909–950; doi: 10.1152/PHYSREV.00026.2013
8.
RamachandraCJA, CongS, ChanX, et al.Oxidative stress in cardiac hypertrophy: From molecular mechanisms to novel therapeutic targets. Free Radic Biol Med, 2021; 166:297–312; doi: 10.1016/J.FREERADBIOMED.2021.02.040
9.
KumarA, DograS, PrakashA. Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against d-galactose induced senescence in mice. Naunyn Schmiedebergs Arch Pharmacol, 2009; 380(5):431–441; doi: 10.1007/S00210-009-0442-8
10.
Poole-WilsonPA, SwedbergK, ClelandJG, et al.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003; 362(9377):7–13; doi: 10.1016/S0140-6736(03)13800-7
11.
HtetL, AungH, CarlosJ, et al.Therapeutic potential and recent advances on targeting mitochondrial dynamics in cardiac hypertrophy: A concise review. Mol Ther Nucleic Acids, 2021; 25:416–443; doi: 10.1016/j.omtn.2021.06.006
12.
PuhlSL. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia. Biochim Biophys Acta Mol Cell Res, 2020; 1867(3):118462; doi: 10.1016/J.BBAMCR.2019.03.009
13.
SierraS, LuquinN, Navarro-OtanoJ. The endocannabinoid system in cardiovascular function: Novel insights and clinical implications. Clin Auton Res, 2017; 28(1):35–52; doi: 10.1007/S10286-017-0488-5
14.
DuerrGD, HeinemannJC, DunkelS, et al.Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. Life Sci, 2013; 92(20–21):976–983; doi: 10.1016/J.LFS.2013.03.014
15.
ChanJZ, DuncanRE. Regulatory effects of cannabidiol on mitochondrial functions: A review. Cells, 2021; 10(5); doi: 10.3390/CELLS10051251
16.
Velez-PardoC, Jimenez-Del-RioM, Lores-ArnaizS, et al.protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure. Neurochem Res, 2010; 35(9):1323–1332; doi: 10.1007/S11064-010-0188-1
17.
HaoE, MukhopadhyayP, CaoZ, et al.Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med, 2015; 21(1):38–45; doi: 10.2119/MOLMED.2014.00261
18.
SchurmanLD, LuD, KendallDA, et al.Molecular mechanism and cannabinoid pharmacology HHS public access author manuscript. Handb Exp Pharmacol, 2020; 258:323–353; doi: 10.1007/164_2019_298
19.
SubramaniamVN, MenezesAR, DeSchutterA, et al.The cardiovascular effects of marijuana: Are the potential adverse effects worth the high? Mo Med, 2019; 116(2):146–153.
20.
García-RivasG, LozanoO, RamosM, et al.Cannabidiol therapy for chronic heart failure prevents cardiac hypertrophy and contractile dysfunction by reducing mitochondrial ros generation in a murine model. J Card Fail, 2022; 28(5):S103; doi: 10.1016/j.cardfail.2022.03.263
21.
RochaL, Frías-SoriaCL, OrtizJG, et al.Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy? Epilepsia Open, 2020; 5(1):36–49; doi: 10.1002/EPI4.12376
22.
EnnisIL, GarciarenaCD, EscuderoEM, et al.Normalization of the calcineurin pathway underlies the regression of hypertensive hypertrophy induced by Na+/H+ exchanger-1 (NHE-1) inhibition. Can J Physiol Pharmacol, 2007; 85(3–4):301–310; doi: 10.1139/Y06-072
23.
LangRM, BierigM, DevereuxRB, et al.Fication: A Report from the american society of echocardiography’s guidelinrecommendations for chamber quanties and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr, 2005; 18(12):1440–1463; doi: 10.1016/J.ECHO.2005.10.005
24.
EscuderoEM, Camilión de HurtadoMC, Gustavo PérezN, et al.Echocardiographic assessment of left ventricular midwall mechanics in spontaneously hypertensive rats. Eur J Echocardiogr, 2004; 5(3):169–175; doi: 10.1016/J.EUJE.2003.11.004
25.
GarciarenaCD, CaldizCI, PortianskyEL, et al.Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart. J Appl Physiol (1985), 2009; 106(4):1325–1331; doi: 10.1152/japplphysiol.91300.2008
26.
YevesAM, BurgosJI, MedinaAJ, et al.Cardioprotective role of IGF-1 in the hypertrophied myocardium of the spontaneously hypertensive rats: A key effect on NHE-1 activity. Acta Physiol (Oxf), 2018; 224(2):e13092; doi: 10.1111/APHA.13092
27.
OmmatiMM, MobasheriA, MaY, et al.Taurine mitigates the development of pulmonary inflammation, oxidative stress, and histopathological alterations in a rat model of bile duct ligation. Naunyn Schmiedebergs Arch Pharmacol, 2022; 395(12):1557–1572; doi: 10.1007/s00210-022-02291-7
28.
MedinaAJ, IbáñezAM, Diaz-ZegarraLA, et al.Cardiac up-regulation of NBCe1 emerges as a beneficial consequence of voluntary wheel running in mice. Arch Biochem Biophys, 2020; 694:108600; doi: 10.1016/j.abb.2020.108600
29.
FedericoM, PortianskyEL, SommeseL, et al.Calcium‐calmodulin‐dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance. J Physiol, 2017; 595(12):4089–4108; doi: 10.1113/JP273714
30.
FedericoM, ZavalaM, VicoT, et al.CaMKII activation in early diabetic hearts induces altered sarcoplasmic reticulum-mitochondria signaling. Sci Rep, 2021; 11(1):20025; doi: 10.1038/S41598-021-99118-X
PardoAC, RinaldiGJ, MoscaSM. Mitochondrial calcium handling in normotensive and spontaneously hypertensive rats: Correlation with systolic blood pressure levels. Mitochondrion, 2017; 20:75–81; doi: 10.1016/J.MITO.2014.12.003
33.
Espinosa-JovelC. Cannabinoids in epilepsy: Clinical efficacy and pharmacological considerations. Neurologia (Engl Ed), 2023; 38(1):49–55; doi: 10.1016/J.NRL.2020.02.005
34.
Pędzińska-BetiukA, WeresaJ, SchlickerE, et al.Chronic cannabidiol treatment reduces the carbachol-induced coronary constriction and left ventricular cardiomyocyte width of the isolated hypertensive rat heart. Toxicol Appl Pharmacol, 2021; 411:115368; doi: 10.1016/j.taap.2020.115368
35.
LuY, AkinwumiBC, ShaoZ, et al.Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes. J Cardiovasc Pharmacol, 2014; 64(5):420–430; doi: 10.1097/FJC.0000000000000134
36.
LuY, LeeDI, ChowdhurySR, et al.Activation of cannabinoid receptors attenuates endothelin-1–induced mitochondrial dysfunction in rat ventricular myocytes. J Cardiovasc Pharmacol, 2020; 75(1):54–63; doi: 10.1097/FJC.0000000000000758
37.
VazquezA, Sanchez-RodriguezE, VargasF, et al.cardioprotective effect of a virgin olive oil enriched with bioactive compounds in spontaneously hypertensive rats. Nutrients, 2019; 11(8); doi: 10.3390/NU11081728
38.
Al-ShudiefatAAR, LudkeA, MalikA, et al.Olive oil protects against progression of heart failure by inhibiting remodeling of heart subsequent to myocardial infarction in rats. Physiol Rep, 2022; 10(15):e15379; doi: 10.14814/PHY2.15379
39.
BukhariIA, MohamedOY, AlmotrefiAA, et al.cardioprotective effect of olive oil against ischemia reperfusion-induced cardiac arrhythmia in isolated diabetic rat heart. Cureus, 2020; 12(2):e7095; doi: 10.7759/CUREUS.7095
40.
RemiszewskiP, Jarocka-KarpowiczI, BiernackiM, et al.Chronic cannabidiol administration fails to diminish blood pressure in rats with primary and secondary hypertension despite its effects on cardiac and plasma endocannabinoid system, oxidative stress and lipid metabolism. Int J Mol Sci, 2020; 21(4); doi: 10.3390/ijms21041295
41.
DziemitkoS, Harasim-SymborE, ChabowskiA. How do phytocannabinoids affect cardiovascular health? An update onthe most common cardiovascular diseases. Ther Adv Chronic Dis, 2023; 14:20406223221143239; doi: 10.1177/20406223221143239
42.
MatsuokaH, NakataM, KohnoK, et al.Chronic l-Arginine Administration Attenuates Cardiac Hypertrophy in Spontaneously Hypertensive Rats. Hypertens, 1996; 27(1):14–18; doi: 10.1161/01.HYP.27.1.14
43.
ThandapillySJ, WojciechowskiP, BehbahaniJ, et al.Resveratrol Prevents the Development of Pathological Cardiac Hypertrophy and Contractile Dysfunction in the SHR Without Lowering Blood Pressure. Am J Hypertens, 2010; 23(2):192–196; doi: 10.1038/AJH.2009.228
44.
Abu ShelbayehO, ArroumT, MorrisS, et al.PGC-1α is a master regulator of mitochondrial lifecycle and ROS stress response. Antioxidants (Basel), 2023; 12(5); doi: 10.3390/antiox12051075
45.
YangD, LiuHQ, LiuFY, et al.Mitochondria in pathological cardiac hypertrophy research and therapy. Front Cardiovasc Med, 2021; 8:822969; doi: 10.3389/FCVM.2021.822969/BIBTEX
46.
LehmanJJ, KellyDP. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol, 2002; 29(4):339–345.
47.
TangY, MiC, LiuJ, et al.Compromised mitochondrial remodeling in compensatory hypertrophied myocardium of spontaneously hypertensive rat. Cardiovasc Pathol, 2014; 23(2):101–106; doi: 10.1016/j.carpath.2013.11.002
48.
Ventura-ClapierR, GarnierA, VekslerV. Transcriptional control of mitochondrial biogenesis: The central role of PGC-1 α. Cardiovasc Res, 2008; 79(2):208–217.
49.
LuZ, XuX, HuX, et al.PGC-1α regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid Redox Signal, 2010; 13(7):1011–1022; doi: 10.1089/ars.2009.2940
50.
FanH, HeZ, HuangH, et al.Mitochondrial quality control in cardiomyocytes: A critical role in the progression of cardiovascular diseases. Front Physiol, 2020; 11:252; doi: 10.3389/FPHYS.2020.00252
51.
TongM, SaitoT, ZhaiP, et al.mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. Circ Res, 2019; 124(9):1360–1371; doi: 10.1161/CIRCRESAHA.118.314607
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
